Welcome to our dedicated page for VERACYTE SEC filings (Ticker: VCYT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Veracyte, Inc. filings document the regulatory record for a Nasdaq-listed cancer diagnostics company with a portfolio that includes Decipher, Afirma, Prosigna, and bladder cancer diagnostics. The company’s Form 8-K reports primarily cover operating and financial results, preliminary financial and testing-volume estimates, and material corporate events.
Veracyte’s proxy and governance filings disclose shareholder voting matters, board and executive compensation practices, equity award information, and governance procedures. Other material-event filings address officer appointments, compensatory arrangements, capital-structure disclosures, and formal exhibits tied to financial reporting and corporate actions.
Veracyte Director Evan Jones received a grant of 9,321 restricted stock units (RSUs) on June 18, 2025. Following this transaction, Jones beneficially owns a total of 43,664 shares directly.
Key terms of the RSU grant:
- RSUs vest in full on the first anniversary of the grant date
- Alternative vesting occurs immediately prior to the company's next annual stockholder meeting, if earlier
- Accelerated vesting provision triggers upon a change in control
- Grant price: $0
The Form 4 was filed on June 23, 2025, within the required reporting window. The transaction was executed under transaction code 'A' indicating an acquisition of securities. This equity grant appears to be part of the company's director compensation program.
Veracyte Director Robert S. Epstein received a grant of 9,321 restricted stock units (RSUs) on June 18, 2025. Following this transaction, Epstein's direct ownership increased to 73,919 shares.
Key terms of the RSU award:
- Vesting occurs in full on the first anniversary of the grant date
- Alternative vesting trigger: immediately prior to the company's next annual meeting of stockholders, if earlier
- Accelerated vesting provision in the event of a change in control
- Grant price: $0
The Form 4 was filed on June 23, 2025, within the required reporting window. The transaction was executed under transaction code 'A' indicating an acquisition of securities. This equity grant appears to be part of Veracyte's director compensation program.
Form 4 filing for Veracyte, Inc. (VCYT) discloses that director Eliav Barr received 9,321 restricted stock units (RSUs) on 18-Jun-2025. The grant price is shown as $0 because RSUs are awarded, not purchased. After the award, Barr’s direct ownership rises to 51,189 common shares.
The RSUs vest 100 % on the first anniversary of the grant or immediately before the next annual shareholder meeting, whichever occurs first. Full vesting also accelerates upon a change-in-control event. No derivative transactions were reported, and no sales occurred.
This filing signals routine board compensation rather than an open-market purchase. While it incrementally increases insider alignment with shareholders, the share count is small and has minimal dilution impact for Veracyte’s ~72 million outstanding shares (figure not in filing). Investors typically view RSU awards as neutral to slightly positive, given the absence of cash outlay and the long-term incentive structure.
Veracyte, Inc. (VCYT) – Form 4 Insider Filing
Director Thomas F. Miller reported the award of 9,321 restricted stock units (RSUs) on 18 June 2025. The RSUs were granted at no cost as part of routine director compensation and will vest in full on the first anniversary of the grant date or immediately before the company’s next annual shareholders’ meeting, whichever occurs first. Vesting also accelerates upon a change in control. Following the grant, Miller’s direct beneficial ownership increased to 25,828 common shares. No open-market purchases, sales, or derivative transactions were disclosed. The filing represents a standard equity compensation event and results in only immaterial dilution relative to Veracyte’s total shares outstanding.
Veracyte, Inc. (VCYT) – Form 4 insider transaction
On 18 June 2025, non-employee director David Brent Shafer was granted 9,321 restricted stock units (RSUs) at a cost basis of $0.00. The award increases his direct beneficial ownership to 25,828 common shares.
The RSUs vest in full on the earlier of (i) the first anniversary of the grant date or (ii) immediately prior to the company’s next annual shareholder meeting, with full acceleration upon a change-in-control. No derivative securities were reported.
This filing reflects routine director equity compensation intended to align board and shareholder interests; it does not involve an open-market purchase or sale and therefore has limited immediate market impact.
Veracyte, Inc. (VCYT) filed an 8-K to disclose the voting results of its 17 June 2025 Annual Meeting and related governance actions. Stockholders elected all seven director nominees with support levels ranging from 93.8% to 98.3% of votes cast (excluding broker non-votes). Ernst & Young LLP was ratified as independent auditor for FY-2025 with 99.7% approval.
A key item was a 2.5 million-share increase to the 2023 Equity Incentive Plan. The amendment passed with 72.6% of votes cast (50.6 m For, 19.1 m Against). Assuming full issuance, potential dilution equals roughly 3.4% of the 73.3 million shares outstanding reported in the company’s February 2025 10-K. While the plan expansion strengthens Veracyte’s ability to attract and retain talent in a competitive diagnostics market, it also modestly dilutes existing holders.
Shareholders backed executive compensation in a non-binding “say-on-pay” vote (97.3% approval) and endorsed an annual frequency for future say-on-pay votes (96.2% choosing one-year cadence). The Board has adopted this schedule until at least the 2031 meeting.
Overall, the meeting reinforced management’s governance platform, maintained auditor continuity, and provided additional equity capacity. No immediate financial results or operational updates were included; therefore, market impact is likely limited to perceptions around future dilution and compensation alignment.